How should an adult surgical site infection be managed, including wound assessment, antibiotic selection for superficial versus deep infections, and considerations for penicillin allergy, MRSA, renal or hepatic impairment, and prosthetic involvement?

Surgical Site Infection Management

For surgical site infections, perform immediate suture removal and incision/drainage, then stratify treatment based on infection depth and anatomic location: superficial infections without systemic signs require local wound care alone, while infections with systemic toxicity (fever, erythema >5cm, or prosthetic involvement) mandate systemic antibiotics tailored to surgical site—use cefazolin/cephalexin for trunk/extremity, add anaerobic coverage (metronidazole) for axilla/perineum, and broad polymicrobial coverage for deep/necrotizing infections. 1

Initial Assessment and Wound Management

Remove sutures and perform incision and drainage as the primary intervention for all surgical site infections 1. This mechanical intervention takes priority over antibiotics in most cases.

Determine infection depth and systemic involvement:

• Measure erythema extension from wound edge
• Check temperature (>38°C indicates systemic response)
• Assess for signs of deeper infection: fluctuance, crepitus, tissue necrosis
• Evaluate hemodynamic stability and mental status

Antibiotic Decision Algorithm

Superficial SSI Without Systemic Signs

No routine antibiotics needed 1. Focus on:

• Wound care and drainage
• Elevation of affected area
• Treatment of predisposing factors (edema, obesity)

Superficial SSI With Systemic Response

Add systemic antibiotics when erythema extends >5cm from wound edge, temperature elevation present, or significant induration 1.

Antibiotic selection by anatomic location:

Trunk or extremity (away from axilla/perineum):

• First-line: Cefazolin 0.5-1g IV q8h or cephalexin 500mg PO q6h
• Alternative: Oxacillin/nafcillin 2g IV q6h
• If MRSA suspected: Add vancomycin 15mg/kg IV q12h 1

Axilla or perineum (anaerobic coverage required):

• Metronidazole 500mg IV q8h PLUS
• Ciprofloxacin 400mg IV q12h (or 750mg PO q12h), OR
• Levofloxacin 750mg IV q24h, OR
• Ceftriaxone 1g IV q24h 1

Intestinal or genitourinary tract surgery:

• Single-drug: Piperacillin-tazobactam 3.375g q6h or 4.5g q8h IV
• Alternative: Ertapenem 1g IV q24h
• Combination: Ceftriaxone 1g q24h + metronidazole 500mg q8h IV 1

Deep or Necrotizing Infection

Obtain immediate surgical consultation 1. These infections carry significant mortality risk and require aggressive intervention.

Empiric broad-spectrum coverage (polymicrobial or monomicrobial):

• Vancomycin or linezolid PLUS piperacillin-tazobactam or carbapenem
• Alternative: Vancomycin PLUS ceftriaxone AND metronidazole 1

This broad coverage addresses mixed aerobic-anaerobic organisms and community-acquired MRSA until cultures guide definitive therapy.

Penicillin Allergy Considerations

Critical caveat: Up to 98% of penicillin allergy labels are incorrect when tested 2. Reported penicillin allergy increases SSI risk by 50% due to receipt of inferior second-line antibiotics 3.

Risk stratification approach:

• Low-risk penicillin allergy history (distant, non-severe): Consider cephalosporin use (cross-reactivity <2%)
• High-risk history (anaphylaxis, Stevens-Johnson): Avoid all β-lactams

Alternative regimens when β-lactams contraindicated:

• Trunk/extremity: Vancomycin 15mg/kg IV q12h or SMX-TMP 160-800mg PO q6h 1
• With anaerobic coverage needed: Vancomycin + metronidazole + fluoroquinolone

The evidence shows patients with penicillin allergy labels receive more clindamycin (49% vs 3%), vancomycin (35% vs 3%), and gentamicin (24% vs 3%), all associated with worse outcomes 3. Between 112-124 patients need allergy evaluation to prevent one SSI 3.

MRSA-Specific Considerations

MRSA colonization significantly increases SSI risk even after successful eradication therapy 4. Previously colonized patients undergoing lower limb joint replacement face particularly high risk (6.7% SSI rate, with 4.4% deep infections) 4.

When MRSA suspected or documented:

• Add vancomycin 15mg/kg IV q12h to empiric regimen
• Consider linezolid for vancomycin-intolerant patients
• Deep infections with prosthetic material: Never use empiric antibiotics alone—obtain cultures first, then combine surgical debridement with organism-specific therapy 5

Prosthetic Material Involvement

Infections involving prosthetic material require fundamentally different management 5:

• Empiric antibiotics are contraindicated—obtain cultures before treatment
• Surgical debridement is mandatory
• Prolonged organism-specific antimicrobial therapy required
• Consider graft explantation for persistent infection

Renal and Hepatic Impairment Adjustments

Renal impairment:

• Vancomycin: Dose by trough levels (10-15 mcg/mL for SSI)
• Cephalosporins: Reduce frequency (cefazolin to q12-24h if CrCl <35)
• Fluoroquinolones: Reduce dose by 50% if CrCl <30
• Ertapenem: 500mg daily if CrCl <30

Hepatic impairment:

• Avoid metronidazole in severe hepatic dysfunction
• Reduce piperacillin-tazobactam dosing in Child-Pugh C
• Linezolid requires no adjustment

Common Pitfalls

1. Using antibiotics for superficial SSI without systemic signs—this promotes resistance without benefit 1
2. Accepting penicillin allergy labels without verification—leads to 50% increased SSI risk 3
3. Starting empiric antibiotics before cultures in prosthetic infections—compromises diagnostic accuracy and treatment success 5
4. Inadequate source control—antibiotics cannot compensate for failure to drain or debride 1
5. Insufficient anaerobic coverage for groin/perineal infections—leads to treatment failure 1